Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2A6, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2A6 Kits (4) and CYP2A6 Proteins (3) and many more products for this protein.
Showing 10 out of 105 products:
Human Polyclonal CYP2A6 Primary Antibody for WB - ABIN2801900
Miles, Bickmore, Brook, McLaren, Meehan, Wolf: Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. in Nucleic acids research 1989
Show all 4 references for 2801900
Human Polyclonal CYP2A6 Primary Antibody for ELISA, WB - ABIN1534381
Yamano, Tatsuno, Gonzalez: The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. in Biochemistry 1990
Polymorphisms within the CYP2A6 gene are not a significant cause of high skatole levels.
a greater CYP2A6 activity causes smokers to smoke more extensively and be exposed to higher levels of carcinogens, resulting in an increased risk for lung cancer.
Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype
We conducted a genome-wide association study (GWAS) of plasma caffeine, paraxanthine, theophylline, theobromine and paraxanthine/caffeine ratio. A single SNP at 6p23 (near CD83 (show CD83 Antibodies)) and several SNPs at 7p21 (near AHR (show AHR Antibodies)), 15q24 (near CYP1A2 (show CYP1A2 Antibodies)) and 19q13.2 (near CYP2A6) met GW-significance (P < 5 x 10-8) and were associated with one or more metabolites
study demonstrated a strong dose-dependent association between reduced CYP2A6 activity determined by genotypes and reduced risk of lung cancer
Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank
drug and the major metabolites were compared with the kinsenoside-cotreated samples. The effect of kinsenoside was negligible on the enzyme activity of all the CYP (show PPIG Antibodies) isozymes tested even though CYP2A6 was slightly inhibited at higher concentrations.
CYP2A6 gene variants were associated with markedly reduced nicotine and cotinine clearances.
CYP2A6 polymorphisms are associated with poor response to chemotherapy in gastric cancer.
Combined 3D-QSAR and docking procedures yielded precise information about the common and distinct interactions of inhibitors and the enzyme active sites of CYP2A6.
P450 (show CYP2B6 Antibodies) 2A13 is one of the important enzymes that oxidizes polycyclic aromatic hydrocarbons
This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3\; however, it has been renamed CYP2A6.
, cytochrome p450 2A6
, 1,4-cineole 2-exo-monooxygenase
, cytochrome P450 2A6
, cytochrome P450 IIA3
, cytochrome P450(I)
, cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6
, flavoprotein-linked monooxygenase
, xenobiotic monooxygenase